56921-01-8

Basic information

• Product Name: Methyl 5-Methyl-4-nitrothiophene-2-carboxylate
• Synonyms: Methyl 5-Methyl-4-nitrothiophene-2-carboxylate
• CAS NO: 56921-01-8
• Molecular Formula: C₇H₇NO₄S
• Molecular Weight: 201.19978
• Mol File: 56921-01-8.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 328.3°Cat760mmHg
• Flash Point: 152.4°C
• Appearance: /
• Density: 1.388g/cm³
• Vapor Pressure: 0.000191mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 5-Methyl-4-nitrothiophene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-Methyl-4-nitrothiophene-2-carboxylate(56921-01-8)
• EPA Substance Registry System: Methyl 5-Methyl-4-nitrothiophene-2-carboxylate(56921-01-8)

Safety Data

• Hazardous Substances Data: 56921-01-8(Hazardous Substances Data)

Usage

General Description

Methyl 5-Methyl-4-nitrothiophene-2-carboxylate is a chemical compound with the molecular formula C9H9NO4S. It is a yellow crystalline solid that is commonly used in the synthesis of organic compounds. Methyl 5-Methyl-4-nitrothiophene-2-carboxylate is a derivative of thiophene, a five-membered aromatic ring with one sulfur atom. The presence of a nitro group and a methyl ester in the structure gives this compound unique chemical properties, making it suitable for various applications in the pharmaceutical and agrochemical industries. Additionally, it has been reported to exhibit biological activities and can serve as an important building block in organic synthesis.

InChI:InChI=1/C7H7NO4S/c1-4-5(8(10)11)3-6(13-4)7(9)12-2/h3H,1-2H3

Upstream product

• 16494-36-3 2-iodo-5-methylthiophene 
• 67-56-1 methanol 
• 36050-35-8 5-methyl-4-nitro-thiophene-2-carboxylic acid 
• 24647-78-7 methyl 4-nitrothiophene-2-carboxylate 
• 13138-70-0 4-nitro-2-thiophenecarboxylic acid 
• 57500-53-5 4-nitrothiophene-2-carbaldehyde 
• 5380-42-7 thiophene-2-carboxylic acid methyl ester 
• 64-19-7 acetic acid 
• 75735-43-2 4,5-dinitro-2-methoxycarbonylthiophen 
• 19432-69-0 methyl 5-methylthiophene-2-carboxylate 
• 1918-79-2 2-methylthiophene-5-carboxylic acid 

Downstream Products

• 353269-67-7 2-Benzylidenmethyl-3-nitro-5-thiophen-carbonsaeure 
• 1001608-59-8 5-[2-(2-fluoro-phenyl)-quinolin-6-yl]-4H-thieno[3,2-b]pyrrole-2-carboxylic acid methyl ester 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula (I), or a pharmaceutically acceptable salt or composition thereof The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.

Dihydro pyridine compound, its composition, preparation method and use

Disclosed dihydropyridine compounds are the compounds possessing the following general formula (I) as shown in the specification, wherein R1 is selected from hydrogen, halogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic groups, substituted heterocyclic groups, ester group and amide group; R2 is selected from hydrogen, cyanogroup, alkyl, substituted alky, alkenyl, substituted alkenyl and acyl; or R2 and R3 form a fused ring; R3 is selected from alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; or R3 and R2 or R4 form a fused ring; R4 is selected from hydrogen, alkyl and substituted alkyl; or R4 and R3 or R5 form a fused ring; R5 is selected form alkyl, substituted alky, aryl, substituted aryl, heteroaryl and substituted heteroaryl; or R5 and R4 form a fused ring. The invention also discloses a preparation method of the compounds of the general formula (I), compositions containing the compounds of the general formula (I), and applications of the compositions to medicaments for treating cancers.

Discovery of (S)-1-(1-(Imidazo[1,2- a ]pyridin-6-yl)ethyl)-6-(1-methyl-1 H -pyrazol-4-yl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal-Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

HGF/c-Met signaling has been implicated in human cancers. Herein we describe the invention of a series of novel triazolopyrazine c-Met inhibitors. The structure-activity relationship of these compounds was investigated, leading to the identification of compound 28, which demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.